Luis M. Montuenga, PhD, on Noninvasive Biomarkers in Lung Cancer Screening
IASLC 2020 World Conference on Lung Cancer in SingaporeLuis M. Montuenga, PhD, of the University of Navarra, discusses the potential contributions of biomarkers, promising biomarker panels being tested and published, the need to standardize biospecimen collection, and how to improve the sensitivity of these biomarkers (Abstract PL05.06).
Related Videos
Silvia Novello, MD, PhD, on NSCLC: Pharmacogenomics-Driven vs Standard Adjuvant Chemotherapy
Roy S. Herbst, MD, PhD, on NSCLC: Osimertinib and Patient-Reported Outcomes
Roy S. Herbst, MD, PhD, of Yale University, discusses two key abstracts from the ADAURA trial: the use of osimertinib as adjuvant therapy for resected EGFR-mutated n...
Fred R. Hirsch, MD, PhD, on Lung Cancer: Survival and Tumor Mutation Burden
Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, discusses Lung-MAP studies in which a higher tumor mutation burden determined by next-generation sequencing was linked...
Jill Feldman: A Determined Cancer Survivor Shares Her Story of a Family Devastated by Lung Cancer
Jill Feldman, a patient advocate who has lost five family members to lung cancer and is herself a 12-year cancer survivor living with EGFR-positive disease, describe...
Martin Reck, MD, PhD, on NSCLC: Pembrolizumab Plus Ipilimumab in First-Line Treatment
Martin Reck, MD, PhD, of the LungenClinic, discusses findings of the KEYNOTE-598 study, which showed that pembrolizumab plus ipilimumab was more toxic and offered no more ben...
